Kinase inhibitor which inhibits mTOR, controlling cell division, resulting in the arrest of growth of tumor cells. Inhibited activity of mTOR resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.

25mg infused over a 30-60 minute period once a week. Treat until disease progression or unacceptable toxicity.

Indicated for the treatment of advanced renal cell carcinoma.

The most common adverse reactions are rash, asthenia, mucositis, nausea, edema, and anorexia. The most common laboratory abnormalities are anemia, hyperglycemia, hyperlipemia, hypertriglyceridemia, elevated alkaline phosphatase, elevated serum creatinine, lymphopenia, hypophosphatemia, thrombocytopenia, elevated AST, and leukopenia.

Pretreat with prophylactic IV diphenhydramine 25-50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose.

To treat hypersensitivity reactions, stop infusion and treat with antihistamine. Drug may be restarted at physician discretion at a slower rate.

Hyperglycemia and hyperlipemia are likely and may require treatment. Monitor glucose and lipid profiles.

Monitor for symptoms or radiographic changes of interstitial lung disease.

Bowel perforation may occur. Evaluate fever, abdominal pain, bloody stools, and/or acute abdomen promptly.

Renal failure, sometimes fatal, has occurred. Monitor renal function at baseline and throughout treatment.

Due to abnormal wound healing, use with caution in the perioperative period.

Live vaccinations and close contact with those who received live vaccines should be avoided.

Women of childbearing potential should be advised of the potential hazard to the fetus and to avoid becoming pregnant.